Contributions
Abstract: PB1456
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Angioimmunoblastic T-cell lymphoma (AITCL) is one of the aggressive histological variants of peripheral T-cell lymphomas. About 70% of patients receiving first-line treatment develop a relapse or a refractory course. There are currently no treatment standards for relapsed/refractory (r/r) AITCL. A number of new therapeutic approaches aime to improve the results in patients with r/r AITCL, including immunotherapy with an effect not only on tumor cells, but also on cells of the microenvironment.
Aims
We want to demonstrate a case of successful treatment Brentuximab vedotin of CD30-negative angioimmunoblastic T-cell lymphoma.
Methods
A 55-year-old woman was diagnosed with angioimmunoblastic T-cell lymphoma who presented with IVB stage of disease with involvement of the cervical, supraclavicular lymph nodes, palatine tonsils, intrathoracic, axillary lymph nodes, intra-abdominal, retroperitoneal lymph nodes, iliac, inguinal lymph nodes, spleen, skin and bone marrow. The patient underwent several lines of chemotherapy and immunotherapy without achieving an effect (СHOP, GDP, CsA, 5-Azacytidine). After treatment, the therapeutic effects were evaluated by PET-CT. The tumor cells did not have CD30 expression, but due to the presence of CD30 expression on healthy cells of the microenvironment, it was decided to use Brentuximab vedotin (Bv) as a salvage-therapy.
Results
On Bv therapy, a partial response was achieved with an improvement in the quality of life (13 injections were performed in total - 4 in combination with Bendamustine and 3 with Rituximab). Therapy was continued with lenalidomide, resulting in a complete response.
Conclusion
This clinical case demonstrates that complete response was achieved by the effect of drugs on microenvironment but not on tumor cells, which emphasizes the immune dependence of this histological variant of PTCL.
Keyword(s): Angioimmunoblastic T-cell lymphoma
Abstract: PB1456
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Angioimmunoblastic T-cell lymphoma (AITCL) is one of the aggressive histological variants of peripheral T-cell lymphomas. About 70% of patients receiving first-line treatment develop a relapse or a refractory course. There are currently no treatment standards for relapsed/refractory (r/r) AITCL. A number of new therapeutic approaches aime to improve the results in patients with r/r AITCL, including immunotherapy with an effect not only on tumor cells, but also on cells of the microenvironment.
Aims
We want to demonstrate a case of successful treatment Brentuximab vedotin of CD30-negative angioimmunoblastic T-cell lymphoma.
Methods
A 55-year-old woman was diagnosed with angioimmunoblastic T-cell lymphoma who presented with IVB stage of disease with involvement of the cervical, supraclavicular lymph nodes, palatine tonsils, intrathoracic, axillary lymph nodes, intra-abdominal, retroperitoneal lymph nodes, iliac, inguinal lymph nodes, spleen, skin and bone marrow. The patient underwent several lines of chemotherapy and immunotherapy without achieving an effect (СHOP, GDP, CsA, 5-Azacytidine). After treatment, the therapeutic effects were evaluated by PET-CT. The tumor cells did not have CD30 expression, but due to the presence of CD30 expression on healthy cells of the microenvironment, it was decided to use Brentuximab vedotin (Bv) as a salvage-therapy.
Results
On Bv therapy, a partial response was achieved with an improvement in the quality of life (13 injections were performed in total - 4 in combination with Bendamustine and 3 with Rituximab). Therapy was continued with lenalidomide, resulting in a complete response.
Conclusion
This clinical case demonstrates that complete response was achieved by the effect of drugs on microenvironment but not on tumor cells, which emphasizes the immune dependence of this histological variant of PTCL.
Keyword(s): Angioimmunoblastic T-cell lymphoma